Risks and Benefits of Helicobacter pylori Eradication: Current Status
In patients with diseases known to be associated with Helicobacter pylori infection, such as peptic ulcer, treatment of the underlying infection is the standard of care. However, in most major consensus management guidelines, including those published in Canada, widespread testing for H pylori infec...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2002-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2002/202961 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567042664824832 |
|---|---|
| author | Richard H Hunt Carlo Fallone Sander Veldhuyzen van Zanten Phil Sherman Fiona Smaill Alan BR Thomson the Canadian Helicobacter Study Group |
| author_facet | Richard H Hunt Carlo Fallone Sander Veldhuyzen van Zanten Phil Sherman Fiona Smaill Alan BR Thomson the Canadian Helicobacter Study Group |
| author_sort | Richard H Hunt |
| collection | DOAJ |
| description | In patients with diseases known to be associated with Helicobacter pylori infection, such as peptic ulcer, treatment of the underlying infection is the standard of care. However, in most major consensus management guidelines, including those published in Canada, widespread testing for H pylori infection is not recommended. This practice is not encouraged because of insufficient evidence of cost-benefit in gastric cancer prevention, the potential for increases in antibiotic resistance and the controversial hypothesis of potential negative effects of eradication in certain clinical entities. For example, there is insufficient evidence to recommend against eradicating H pylori discovered in a patient with symptoms of gastroesophageal reflux disease. The management guidelines designed specifically in Canada should, therefore, continue to be applied, with H pylori diagnosed and treated in appropriately selected patients. |
| format | Article |
| id | doaj-art-8976a55b40b249d7a550b0e9c90ba36c |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 2002-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-8976a55b40b249d7a550b0e9c90ba36c2025-02-03T01:02:28ZengWileyCanadian Journal of Gastroenterology0835-79002002-01-01161576210.1155/2002/202961Risks and Benefits of Helicobacter pylori Eradication: Current StatusRichard H Hunt0Carlo Fallone1Sander Veldhuyzen van Zanten2Phil Sherman3Fiona Smaill4Alan BR Thomson5the Canadian Helicobacter Study GroupDivision of Gastroenterology, Department of Medicine, McMaster University, Hamilton, Ontario, CanadaDivision of Gastroenterology, Department of Medicine, McGill University, Montreal, Quebec, CanadaDivision of Gastroenterology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, CanadaDivision of Gastroenterology and Nutrition, Department of Pediatrics, University of Toronto, Toronto, Ontario, CanadaDivision of Gastroenterology, Department of Medicine, McMaster University, Hamilton, Ontario, CanadaDivision of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, CanadaIn patients with diseases known to be associated with Helicobacter pylori infection, such as peptic ulcer, treatment of the underlying infection is the standard of care. However, in most major consensus management guidelines, including those published in Canada, widespread testing for H pylori infection is not recommended. This practice is not encouraged because of insufficient evidence of cost-benefit in gastric cancer prevention, the potential for increases in antibiotic resistance and the controversial hypothesis of potential negative effects of eradication in certain clinical entities. For example, there is insufficient evidence to recommend against eradicating H pylori discovered in a patient with symptoms of gastroesophageal reflux disease. The management guidelines designed specifically in Canada should, therefore, continue to be applied, with H pylori diagnosed and treated in appropriately selected patients.http://dx.doi.org/10.1155/2002/202961 |
| spellingShingle | Richard H Hunt Carlo Fallone Sander Veldhuyzen van Zanten Phil Sherman Fiona Smaill Alan BR Thomson the Canadian Helicobacter Study Group Risks and Benefits of Helicobacter pylori Eradication: Current Status Canadian Journal of Gastroenterology |
| title | Risks and Benefits of Helicobacter pylori Eradication: Current Status |
| title_full | Risks and Benefits of Helicobacter pylori Eradication: Current Status |
| title_fullStr | Risks and Benefits of Helicobacter pylori Eradication: Current Status |
| title_full_unstemmed | Risks and Benefits of Helicobacter pylori Eradication: Current Status |
| title_short | Risks and Benefits of Helicobacter pylori Eradication: Current Status |
| title_sort | risks and benefits of helicobacter pylori eradication current status |
| url | http://dx.doi.org/10.1155/2002/202961 |
| work_keys_str_mv | AT richardhhunt risksandbenefitsofhelicobacterpylorieradicationcurrentstatus AT carlofallone risksandbenefitsofhelicobacterpylorieradicationcurrentstatus AT sanderveldhuyzenvanzanten risksandbenefitsofhelicobacterpylorieradicationcurrentstatus AT philsherman risksandbenefitsofhelicobacterpylorieradicationcurrentstatus AT fionasmaill risksandbenefitsofhelicobacterpylorieradicationcurrentstatus AT alanbrthomson risksandbenefitsofhelicobacterpylorieradicationcurrentstatus AT thecanadianhelicobacterstudygroup risksandbenefitsofhelicobacterpylorieradicationcurrentstatus |